Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting

April 26, 2023

https://www.globenewswire.com/news-release/2023/04/26/2655648/0/en/Atreca-Announces-Oral-Presentation-of-ATRC-101-Phase-1b-Study-Data-at-ASCO-2023-Annual-Meeting.html

SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that data from the Phase 1b study of ATRC-101 will be presented during an oral abstract session at the American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois.

Read more at globenewswire.com

Related news for (BCEL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.